China doubles R&D spend – but that doesn’t mean its innovation dilemma is solved
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
@IAM_Alerts Kathi Vidal’s @uspto Director confirmation hearing in front of the Senate Judiciary Committee will take place tomor… https://t.co/tGwuxZjQTG Read more
@IAM_Alerts RT @EPOorg: Once again, users have voted the EPO number #1 among the world’s five largest #patent offices for the quality of its patents an… Read more
@IAM_Alerts IAM understands that Kathi Vidal’s USPTO Director nomination hearing before the Senate Judiciary Committee is set f… https://t.co/q0unBMd4Y7 Read more
@IAM_Alerts While a huge advantage for innovators, PTEs in China are set to create new regulatory headaches for pharma IP teams… https://t.co/yIlbSOJNUy Read more